Long-term safety follow-up for people who received cell or gene therapy
Monitors long-term safety of people previously given AstraZeneca cell or gene therapies.
Plain-language title generated from the registry record
Registry title: LTFU for All Cell and Gene Therapy Studies
Key facts
- Where
- Kashiwa, Kyoto, and Osakasayama-shi, JapanSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06194461, who can take part
Where in Japan
- KashiwaKashiwa, JapanNo longer taking part
- KyotoKyoto, JapanNo longer taking part
- Osakasayama-shiOsakasayama-shi, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06194461
- Record updated
- 27 June 2025
- Original description
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.Read full original descriptionShow less
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Inclusion: The participant has received a cell or gene therapy in another AstraZeneca protocol; Provision of signed and dated, written informed consent before any study-specific procedures.
Exclusion: Not applicable; -.